Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10362/169887Registo completo
| Campo DC | Valor | Idioma |
|---|---|---|
| dc.contributor.author | Georgiadis, Stylianos | - |
| dc.contributor.author | Ørnbjerg, Lykke Midtbøll | - |
| dc.contributor.author | Michelsen, Brigitte | - |
| dc.contributor.author | Kvien, Tore K. | - |
| dc.contributor.author | Giuseppe, Daniela Di | - |
| dc.contributor.author | Wallman, Johan K. | - |
| dc.contributor.author | Závada, Jakub | - |
| dc.contributor.author | Provan, Sella A. | - |
| dc.contributor.author | Kristianslund, Eirik Klami | - |
| dc.contributor.author | Rodrigues, Ana Maria | - |
| dc.contributor.author | Santos, Maria José | - |
| dc.contributor.author | Rotar, Žiga | - |
| dc.contributor.author | Pirkmajer, Katja Perdan | - |
| dc.contributor.author | Nordström, Dan | - |
| dc.contributor.author | Macfarlane, Gary J. | - |
| dc.contributor.author | Jones, Gareth T. | - |
| dc.contributor.author | van der Horst-Bruinsma, Irene | - |
| dc.contributor.author | Hellamand, Pasoon | - |
| dc.contributor.author | Østergaard, Mikkel | - |
| dc.contributor.author | Hetland, Merete Lund | - |
| dc.date.accessioned | 2024-07-22T22:18:33Z | - |
| dc.date.available | 2024-07-22T22:18:33Z | - |
| dc.date.issued | 2024 | - |
| dc.identifier.issn | 0315-162X | - |
| dc.identifier.other | PURE: 95310011 | - |
| dc.identifier.other | PURE UUID: cfbc503d-316e-4cc6-a6d0-617987efe3c0 | - |
| dc.identifier.other | Scopus: 85197769490 | - |
| dc.identifier.other | PubMed: 38621792 | - |
| dc.identifier.uri | http://hdl.handle.net/10362/169887 | - |
| dc.description | Funding Information: On behalf of the EuroSpA Scientific Committee, the authors acknowledge Novartis Pharma AG and IQVIA for supporting the EuroSpA Research Collaboration Network. Publisher Copyright: © 2024 The Journal of Rheumatology. | - |
| dc.description.abstract | Objective. Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.3, 2.1, and 3.5) and investigate the potential improvement of level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states when applying these estimated cut-offs. Methods. We used data from patients with axSpA from 9 European registries initiating a tumor necrosis factor inhibitor. ASDAS-ESR cut-offs were estimated using the Youden index. The level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states was compared against each other. Results. In 3664 patients, mean ASDAS-CRP was higher than ASDAS-ESR at both baseline (3.6 and 3.4, respectively) and aggregated follow-up at 6, 12, or 24 months (1.9 and 1.8, respectively). The estimated ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs were 1.4, 1.9, and 3.3. By applying these cut-offs, the proportion of discordance between disease activity states according to ASDAS-ESR and ASDAS-CRP decreased from 22.93% to 19.81% in baseline data but increased from 27.17% to 28.94% in follow-up data. Conclusion. We estimated the optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-off values. However, applying the estimated cut-offs did not increase the level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states to a relevant degree. Our findings did not provide evidence to reject the established cut-off values for ASDAS-ESR. | en |
| dc.format.extent | 5 | - |
| dc.language.iso | eng | - |
| dc.rights | openAccess | - |
| dc.subject | axial spondyloarthritis | - |
| dc.subject | patient outcome assessment | - |
| dc.subject | registry data | - |
| dc.subject | validation study | - |
| dc.subject | Rheumatology | - |
| dc.subject | Immunology and Allergy | - |
| dc.subject | Immunology | - |
| dc.title | Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate | - |
| dc.type | article | - |
| degois.publication.firstPage | 673 | - |
| degois.publication.issue | 7 | - |
| degois.publication.lastPage | 677 | - |
| degois.publication.title | Journal of Rheumatology | - |
| degois.publication.volume | 51 | - |
| dc.peerreviewed | yes | - |
| dc.identifier.doi | https://doi.org/10.3899/jrheum.2023-1217 | - |
| dc.description.version | publishersversion | - |
| dc.description.version | published | - |
| dc.title.subtitle | Are They Interchangeable? | - |
| dc.contributor.institution | NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) | - |
| Aparece nas colecções: | NMS - Artigos em revista internacional com arbitragem científica | |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| 673.full.pdf | 184,01 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.











